IRVINE, Calif., Sept. 28, 2022 /PRNewswire/ -- Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our ...

Please provide your email address to receive an email when new articles are posted on . MILAN — In this video at the ESCRS meeting, Ramin Khoramnia, MD, presents the results of a trial on the Tecnis ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Please provide your email address to receive an email when new articles are posted on . Bilateral implantation of the Tecnis Synergy IOL showed “very good” outcomes at all distances at 3 months of ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes. 5¶ Experience the ...

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †. 93% of patients become free from glasses at all distances.#4 ‡ TECNIS Odyssey ...